Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer

Broxbam, also known as N-hydroxy-4-{1-methoxy-4-[4′-(3′-bromo-4′,5′-dimethoxyphenyl)-oxazol-5′-yl]-2-phenoxy} butanamide, is a novel chimeric inhibitor that contains two distinct pharmacophores in its molecular structure. It has been previously demonstrated to inhibit the activity of histone deacety...

Descripción completa

Detalles Bibliográficos
Autores principales: Bär, Sofia Isolde, Dittmer, Alexandra, Nitzsche, Bianca, Ter-Avetisyan, Gohar, Fähling, Michael, Klefenz, Adrian, Kaps, Leonard, Biersack, Bernhard, Schobert, Rainer, Höpfner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097774/
https://www.ncbi.nlm.nih.gov/pubmed/35485292
http://dx.doi.org/10.3892/ijo.2022.5363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097774/
https://www.ncbi.nlm.nih.gov/pubmed/35485292
http://dx.doi.org/10.3892/ijo.2022.5363

Ejemplares similares